The FDA has released draft guidance entitled “Assay Migration Studies for In Vitro Diagnostic Devices,” which is designed to present a least burdensome regulatory approach to gaining FDA approval of Class III or certain licensed in vitro diagnostic devices in cases when a previously-approved assay is migrating to a new system for which the assay has not been previously approved or licensed. FDA will accept comments on the draft guidance until April 6, 2009.
- How-to guide How-to guide: How to identify and assess bribery and corruption risk (UK)
- How-to guide How-to guide: What general counsel (GC) need to know about environmental, social and governance (ESG) Recently updated
- How-to guide How-to guide: How to identify and manage antitrust and unfair trade practice risk (USA) Recently updated